Santhera Pharmaceuticals Holding AG (0QN1.L)

9.21 +1.81 (+24.51%) At close: 05:09PM GMT

Santhera Pharmaceuticals Holding AG

Hohenrainstrasse 24
Pratteln 4133
Switzerland
41 61 906 89 50
https://www.santhera.com

Sector(s): 
Industry: 
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Thomas Meier Ph.D.	Founder & Chairman	83.75k	N/A	1962
Mr. Dario Eklund	Chief Executive Officer	814.82k	N/A	1968
Mr. Andrew P. Smith CGMA, FCMA	Chief Financial Officer	N/A	N/A	1963
Mr. Oliver Strub	Executive VP, General Counsel & Secretary	N/A	N/A	1963
Mr. Günther Metz Ph.D.	Head of Business Development & Executive VP	N/A	N/A	1958
Mr. Shabir Hasham M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Stephanie Brown B.Sc., M.B.A.	President of North America	N/A	N/A	1961
Mr. Marc Schrader	Head of Technical Development & Operations	N/A	N/A	N/A
Ms. Eva Kalias	Head of Investor Relations & Communications	N/A	N/A	N/A
Mr. Neville Kodkani M.D.	Head of Global Marketing & Partner Management	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Corporate governance

Santhera Pharmaceuticals Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.